RaQualia Pharma (TSE:4579) Cyclically Adjusted PS Ratio: (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
62 GF Score
Price 円549.00
GF Value 円753.26
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


RaQualia Pharma  (TSE:4579) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


RaQualia Pharma Cyclically Adjusted PS Ratio Related Terms


RaQualia Pharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Cyclically Adjusted PS Ratio Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.84 20.12 9.86 0.00 10.22

RaQualia Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.26 6.31 10.22 7.69 0.00

TSE:4579 vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, RaQualia Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RaQualia Pharma Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RaQualia Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where RaQualia Pharma's Cyclically Adjusted PS Ratio falls into.


TSE:4579
62GF Score
RaQualia Pharma Inc TSE:4579
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

RaQualia Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, RaQualia Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/113.6000*113.6000
=0.000

Current CPI (Jun. 2026) = 113.6000.

RaQualia Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.666 98.100 0.771
201609 1.146 98.000 1.328
201612 3.551 98.400 4.100
201703 21.907 98.100 25.368
201706 2.378 98.500 2.743
201709 7.398 98.800 8.506
201712 40.068 99.400 45.792
201803 19.497 99.200 22.327
201806 2.427 99.200 2.779
201809 4.266 99.900 4.851
201812 10.384 99.700 11.832
201903 17.059 99.700 19.437
201906 9.572 99.800 10.896
201909 7.859 100.100 8.919
201912 47.485 100.500 53.675
202003 5.897 100.300 6.679
202006 11.894 99.900 13.525
202009 9.585 99.900 10.899
202012 25.475 99.300 29.144
202103 31.291 99.900 35.582
202106 31.742 99.500 36.240
202109 14.372 100.100 16.310
202112 55.027 100.100 62.448
202203 16.189 101.100 18.191
202206 52.825 101.800 58.948
202209 21.773 103.100 23.990
202212 48.248 104.100 52.651
202303 17.172 104.400 18.685
202306 29.772 105.200 32.149
202309 22.270 106.200 23.822
202312 18.763 106.800 19.958
202403 29.995 107.200 31.786
202406 35.237 108.200 36.996
202412 0.000 110.700 0.000
202503 44.430 111.100 45.430
202506 24.909 111.700 25.333
202509 33.081 112.000 33.554
202512 69.417 113.000 69.786
202603 31.410 112.700 31.661
202606 0.000 113.600 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円549.00 is trading 27.1% below its estimated GF Value™ of 円753.26. GuruFocus considers RaQualia Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4579:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: 円753.26 vs. price of 円549.00 (27.1% below fair value)
  • GF Score™: 62/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
62GF Score

Get the complete analysis for TSE:4579

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円549.00
Price
円753.26
GF Value